Further, individuals with melanoma and Class I mutations experience better survival with frontline ICI-based therapy than anti-BRAF/MEK therapy, raising questions about the optimal treatment sequencing in NSCLC (16, 30–33). This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.